PGIM India Healthcare Fund
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Growthvine rating: 1/5 — ranked #79 of 84 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹12.12 (as of 2026-09-11) |
|---|
| AUM | ₹103 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Anandha Padmanabhan Anjeneyan |
|---|
| Exit load | 0.5% for redemption within 90 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -14.58% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 108.7% of NIFTY Pharma's upside and 100.2% of its downside.
Market cap allocation
| Large cap | 34.5% |
|---|
| Mid cap | 34.1% |
|---|
| Small cap | 31.3% |
|---|
Concentration
| Top 5 holdings | 42.7% |
|---|
| Top 10 holdings | 64.0% |
|---|
| Total holdings | 29 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 10.9%
- Divis Laboratories Ltd. — 10.4%
- Torrent Pharmaceuticals Ltd. — 9.4%
- Aster DM Healthcare Limited — 6.2%
- Max Healthcare Institute Limited — 5.9%
- Ajanta Pharma Ltd. — 5.2%
- Mankind Pharma Limited — 4.7%
- Clearing Corporation of India Ltd. — 4.3%
- Dr. Lal Pathlabs Limited — 4.1%
- Krishna Institute of Medical Sciences Limited — 3.8%
Top sectors
- Pharma & Biotech — 63.1%
- Healthcare — 27.5%
- Chemicals — 2.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 23.2% | Q1 (Top) | #6 of 76 |
| 2025 | -2.7% | Q3 | #44 of 69 |